Literature DB >> 4048015

Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r.

M Hasenson, B Hartley-Asp, C Kihlfors, A Lundin, J A Gustafsson, A Pousette.   

Abstract

The use of ATP content as a measurement for cell growth was evaluated in the LNCaP prostatic cancer cell line. ATP content was found to correlate well with cell counts and was an easy and reliable method for following the effect of substances on cell growth. During cultivation for 9 days no effect on cell counts or ATP content could be seen when testosterone (10(-10) to 10(-6) M), estradiol-17 beta (10(-10) to 10(-5) M), 5 alpha-DHT (10(-9) to 10(-6) M), prolactin, vitamin A, or antiandrogen was added to the cell medium in different combinations. However, a weak positive effect was seen on the mitotic index when 10 or 100 nM 5 alpha-DHT was added to the cells, whereas 1 microM 5 alpha-DHT inhibited cell growth. Thus despite the fact that this LNCaP line contained 16 fmol androgen receptor/mg protein (Kd 0.6 nM), it is unresponsive to hormones and should be designated LNCaP-r (resistant). Chromosome analysis revealed that a shift in the modal chromosome number had occurred from the original LNCaP line, which could account for the lack of hormonal sensitivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4048015     DOI: 10.1002/pros.2990070208

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

Review 1.  The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.

Authors:  G J van Steenbrugge; M Groen; J W van Dongen; J Bolt; H van der Korput; J Trapman; M Hasenson; J Horoszewicz
Journal:  Urol Res       Date:  1989

2.  Difference in uptake of 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r.

Authors:  M Hasenson
Journal:  Urol Res       Date:  1989

3.  Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.

Authors:  J J König; E Kamst; A Hagemeijer; J C Romijn; J Horoszewicz; F H Schröder
Journal:  Urol Res       Date:  1989

4.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

5.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

6.  Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.

Authors:  M Hansenson; B Lundh; B Hartley-Asp; A Pousette
Journal:  Urol Res       Date:  1988

7.  Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.

Authors:  D A Wolf; P Schulz; F Fittler
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

8.  Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues.

Authors:  R H van Schaik; C D Wierikx; M A Timmerman; M H Oomen; W M van Weerden; T H van der Kwast; G J van Steenbrugge; F H de Jong
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.

Authors:  Björn Johansson; Mohammad R Pourian; Yin-Choy Chuan; Irene Byman; Anders Bergh; See-Tong Pang; Gunnar Norstedt; Tomas Bergman; Ake Pousette
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.